#1 Clinical Trials Search in Europe

Aon-D21

Clinical trials are studying Aon-D21 as an add-on treatment for severe community-acquired pneumonia. The main goal is to assess safety and tolerability, and the trial also looks at how well it works in adults admitted to intensive care or a similar unit.

Table of contents

Trial overview

The available clinical trial data describe one study of Aon-D21 in people with severe community-acquired pneumonia, a serious lung infection that starts outside the hospital.[1] The study is an interventional trial, which means researchers gave a study treatment and measured the results.[1]

Who the study is for

This trial focused on patients with severe community-acquired pneumonia who were admitted to an intensive care unit or a similar high-acuity unit.[1] In simple terms, this means the study population included very sick patients who needed close hospital monitoring and advanced care.[1]

What the study is testing

The trial tested Aon-D21 as an add-on treatment, meaning it was used together with standard care rather than as a replacement.[1] The study compared Aon-D21 with a placebo, which was a 5% glucose infusion that looked like the study treatment but did not contain Aon-D21.[1]

The brief study summary says the main purpose was to assess the safety and tolerability of Aon-D21 in this patient group.[1] Safety means checking for medical problems during the trial, and tolerability means how well patients can handle the treatment.[1]

Trial phase and design

This was a Phase 2 study, which is an early stage that usually looks more closely at safety and whether there are early signs of benefit.[1] The trial included 160 participants and is listed as completed.[1]

What the study measures

The main endpoint was the frequency, severity, and relatedness of treatment-emergent adverse events until Day 28.[1] An adverse event is any medical problem that happens during a study, and treatment-emergent means it starts or gets worse after treatment begins.[1]

The study also tracked serious and non-serious adverse events, so researchers could see both major and less severe medical problems and judge whether they might be linked to Aon-D21.[1] This kind of endpoint helps show whether the study treatment appears safe enough for further research.[1]

Study status and size

The trial NCT05962606 is marked as completed.[1] The enrollment was 160, which is the number of people who joined the study.[1]

Only one trial was provided in the source data, so the current evidence base here is limited to this single Phase 2 study in severe community-acquired pneumonia.[1]

Trial ID Phase Condition studied Status Enrollment
NCT05962606 Phase 2 Severe Community-Acquired Pneumonia Completed 160

FAQ

  • What is being studied in Aon-D21 trials? The trial is testing Aon-D21 as an add-on treatment for severe community-acquired pneumonia. It compares Aon-D21 with placebo, which is a look-alike infusion that does not contain the study drug.
  • Who can take part in the study? The study is for patients with severe community-acquired pneumonia who are admitted to an intensive care unit or a similar unit. The trial data do not list every eligibility rule, so exact participation depends on the study screening process.
  • What phase is the Aon-D21 trial? The trial is a Phase 2 study. Phase 2 trials usually look more closely at safety and early signs of benefit in a specific patient group.
  • What is the main outcome being measured? The main outcome is the frequency, severity, and relatedness of treatment-emergent adverse events up to Day 28. In simple terms, the study checks what side effects happen, how serious they are, and whether they may be linked to the study drug.
  • Is the Aon-D21 study finished? Yes, the trial listed in the source data is completed. It included 160 participants.

Ongoing Clinical Trials on Aon-D21

  • Study on AON-D21 for Patients with Severe Community-Acquired Pneumonia in Intensive Care

    Not recruiting

    1
    Investigated drugs:
    Belgium France Germany Spain

Glossary

  • Severe community-acquired pneumonia: A serious lung infection that starts outside the hospital and is bad enough to need intensive medical care.
  • Add-on treatment: A treatment used together with the usual care, not instead of it.
  • Placebo: A look-alike treatment that does not contain the study drug. It helps researchers compare results fairly.
  • Phase 2: A stage of clinical research that looks at safety and early signs that a treatment may help.
  • Interventional study: A study in which researchers give a treatment and then measure what happens.
  • Intensive care unit: A hospital unit for patients who need very close monitoring and advanced treatment.
  • Adverse event: A medical problem that happens during a study, whether or not it is caused by the study treatment.
  • Treatment-emergent adverse event: A side effect or medical problem that starts or gets worse after the study treatment begins.
  • Serious adverse event: A medical problem that is severe, may be life-threatening, or needs hospital care.
  • Tolerability: How well patients can handle a treatment without too many difficult side effects.
  • Enrollment: The number of people who joined the study.

References